Topics in Health Care From MashupMD

Infectious Disease

Our editors at MashupMD bring you the latest in medicine, health care, and public health from the leading professionals and journals you trust.

CheckMate Trials and a Discussion on Synergistic Power of Lag-3 and PD-1 in Kidney Cancer

Dear readers,

Our previous collection on advanced renal cell carcinoma (aRCC) discussed revisited data and new insights. Today, we would like to highlight more of the roundtable discussions from ASCO GU 2024 moderated by Rana McKay, MD.

First, we included a new discussion between Dr. Katy Beckermann and Dr. Michael Atkins on the potential synergistic power of LAG-3 and PD-1 in kidney cancer. Getting into the roundtables, this collection features segments 4-7, which cover CheckMate-214, 914, 9ER, and 67T. Finally, the panel discussed the future of aRCC. The roundtable coverage and additional content in aRCC can be found on GU Oncology Now.

Kind regards,
Your Editors at MashupMD

  • Mashup Score: 0
    Tweet Tweets with this article
    • Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, and Michael Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, consider the potential of LAG-3 as a checkpoint inhibitor in kidney cancer treatment, highlighting biomarkers for patient selection and the importance of frontline therapy in increasing cure rates.

  • Mashup Score: 0

    Read the full article here

    Tweet Tweets with this article
    • In the fifth segment of the roundtable series, the panel highlighted the CheckMate 9ER study and implications for clinical practice.